H5N1 Vaccination With and Without AS03: Systems Biology Analysis
Status:
Completed
Trial end date:
2014-01-02
Target enrollment:
Participant gender:
Summary
This is a single center, randomized, double-blinded, controlled, Phase I, small targeted
prospective study in healthy male and non-pregnant female subjects, 18 to 49 years old,
inclusive, designed to determine the safety, reactogenicity, and immunogenicity of an
intramuscular subvirion inactivated monovalent influenza A/H5N1 (HA of A/Indonesia/05/2005)
virus vaccine manufactured by Sanofi Pasteur administered at 3.75 mcg per dose given with or
without AS03 adjuvant manufactured by GSK. In the study, each subject will receive two doses
administered 28 days apart. This study will use a systems biology approach to assess the
human early gene and protein signatures expressed at Days 1, 3, 7, and 28 after the first
vaccination. The systems data will be integrated with immunogenicity and reactogenicity data
to develop a systems model of the human immune response to A/H5N1 vaccine with or without
AS03 adjuvant.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)